This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-07. Anything still debated is marked as such rather than presented as settled.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Freely soluble in water | Dissolves readily in aqueous buffer |
| Typical storage temperature | -20 °C or below | Protect from light and moisture |
| Typical analytical method | Reversed-phase HPLC and LC-MS | Purity estimate plus mass confirmation |
| Unit of measure | Milligram per vial | Content varies by vendor |
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Pharmacocybernetics (also known as pharma-cybernetics, cybernetic pharmacy, and cyber pharmacy) is an emerging field that describes the science of supporting drugs and medications use through the application and evaluation of informatics and internet technologies, so as to improve the pharmaceutical care of patients.
== Disorders == Platelet disorders can occur because there are not enough platelets, too many platelets, or the platelets do not function properly. Low platelet concentration is called thrombocytopenia, and is due to either decreased production, increased destruction of platelets, or platelets being sequestered in another part of the body. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms. Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different from those of a normal clot: extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.:
=== Poland: the Catholic Church and Solidarity === Historian Tony Judt, among others, traced communism's collapse back to events in Poland as far back as 16 October 1978, when Karol Wojtyła—Archbishop of Kraków—became the first Polish pope in history. Abandoning his predecessors' cautious Ostpolitik, John Paul II arrived in Warsaw the following June for the first of three pilgrimages to communist Poland, offering the Church not as a passive sanctuary but as an alternative pole of moral and social authority. Communist leaders, faced with the visible enthusiasm the pontiff’s presence elicited, had no viable response, since barring his return would only have deepened his appeal. When Pope John Paul II returned to Warsaw in June 1983 and told an uncomfortable General Wojciech Jaruzelski, on live television, that Poland "must take her proper place among the nations of Europe, between East and West," the Communist leadership could only stand and listen. As Stalin once observed, the Pope has no divisions—yet Wojtyła's visibility and timing emboldened activists who drew up a Charter of Workers' Rights that December, supplying the Polish trade union's eventual base of dissidents and workers with exactly the confidence a state already teetering from its failed food-subsidy strategy could not counter. As a result, Poland's blossoming grassroots Solidarity movement rapidly gained ground with strong popular bases that not only included organized labor, but spread through intellectual networks, and additionally garnered open support from the Catholic Church.
On October 31, a federal judge in Rhode Island cited the Administrative Procedure Act and temporarily ordered the Trump administration to continue SNAP funding. A second federal judge in Boston said the Trump administration's plan to stop SNAP funding during the shutdown was against the law, but did not order payments to resume. On November 7, Justice Ketanji Brown Jackson temporarily froze the lower court order requiring full payment of SNAP. ABC News stated, "at least nine states had already begun issuing SNAP benefits under the direction of the federal agency that operates SNAP," reportedly including California, Wisconsin, Kansas, Pennsylvania, New York, New Jersey, and Vermont. In early November, Trump called for ending the Senate's rule and tradition of the filibuster. On November 6, some Republican senators talked about making a "clean" Continuing Resolution one of the exceptions to the filibuster rule, but it's estimated that this change is unlikely. On November 9, the Senate achieved a 60-vote compromise of a "mini-bus" which will fund certain departments through next September and the rest of government through January 30. SNAP would be funded through September 2026. Senate Republicans agreed to have a vote on the Obamacare funding by the 2nd week of December. Eight Democrats voted with Republicans to end the shutdown. On November 12, the House passed the bill, 222 to 209. Trump then signed it into law.
Sources: en.wikipedia.org
== Works == Gish, Duane T. 15 Scopus Publishers. Gish, Duane T. (1972). Speculations and Experiments on the Origins of Life. New Leaf Pr. ISBN 0-89051-010-5. Gish, Duane T. (1972). Evidence against evolution. Wheaton, Ill: Tyndale House Publishers. ISBN 0-8423-0790-7. Gish, Duane T. (1986) [1972]. Evolution, the fossils say no!. San Diego, Calif: Institute for Creation Research Publishing. ISBN 0-89051-057-1. Gish, Duane T. (1973). Have You Been... Brainwashed?. Seattle, Washington: Life Messengers. p. 32. OCLC 10930514. Hillestad, George M.; Morris, Henry; Gish, Duane T. (1974). Creation: acts, facts, impacts. San Diego, Calif: ICR Pub. Co. ISBN 0-89051-020-2. Gish, Duane T. (1977). Dinosaurs: Those Terrible Lizards. Green forest, Arkansas: Master Books. ISBN 0-89051-039-3. Rohrer, Donald H.; Gish, Duane T. (1978). Up with creation!: ICR acts/facts/impacts, 1976-1977. San Diego, California: Creation-Life Publishers. ISBN 0-89051-048-2. Gish, Duane T.; Wilson, Clifford (1981). Manipulating life, where does it stop?: Genetic engineering. Green Forest, Arkansas: Master Books. ISBN 0-89051-071-7. Gish, Duane T. (1985). Evolution: the challenge of the fossil record. San Diego, Calif: Creation-Life Publishers. ISBN 0-89051-112-8. Gish, Duane T. (1988). Creationist Research 1964-1988. Creation Research Society. ISBN 0-940384-06-X. Bonnie Snellenberger; Gish, Duane T.; D Dish; Earl Snellenberger (1990). The Amazing Story of Creation: From Science and the Bible. Green Forest, Arkansas: Master Books. ISBN 0-89051-120-9.
=== Pharmacokinetics === The drug is rapidly absorbed after oral administration and is widely distributed throughout the body. Biotransformation is low: the drug is predominantly excreted unchanged by the kidneys. The serum half-life of baclofen is roughly 2–4 hours; however, one source gives a half-life of 6.8 hours, using a more complex calculation combining urinary and serum data. It therefore needs to be administered frequently throughout the day to control spasticity appropriately.
Less kidney toxicity has been reported with liposomal formulations (such as AmBisome) and it has become preferred in patients with preexisting renal injury. The integrity of the liposome is disrupted when it binds to the fungal cell wall, but is not affected by the mammalian cell membrane, so the association with liposomes decreases the exposure of the kidneys to amphotericin B, which explains its less nephrotoxic effects. In addition, electrolyte imbalances such as hypokalemia and hypomagnesemia are also common. In the liver, increased liver enzymes and hepatotoxicity (up to and including fulminant liver failure) are common. In the circulatory system, several forms of anemia and other blood dyscrasias (leukopenia, thrombopenia), serious cardiac arrhythmias (including ventricular fibrillation), and even frank cardiac failure have been reported. Skin reactions are also possible, with rash & itching occurring in about 17% of patients, in rare cases it can cause a serious skin reaction known as Drug rash with eosinophilia and systemic symptoms (DRESS). In very rare instances, amphotericin B has also been shown to cause reversible ototoxicity causing tinnitus, vertigo, and temporary hearing loss. While there have been only a few reported cases, the hearing loss was temporary in all of them, with hearing showing improvement two weeks after discontinuing the drug. The analogue AM-2-19 has been engineered to be less toxic to the kidneys.
Sources: en.wikipedia.org
macrophage Any of a class of relatively long-lived phagocytic cells of the mammalian immune system which are activated in response to the presence of foreign materials in certain tissues and subsequently play important roles in antigen presentation, stimulating other types of immune cells, and killing or engulfing parasitic microorganisms, diseased cells, or tumor cells.
==== Quantification ==== Polyphenolic content in vitro can be quantified by volumetric titration. An oxidizing agent, permanganate, is used to oxidize known concentrations of a standard tannin solution, producing a standard curve. The tannin content of the unknown is then expressed as equivalents of the appropriate hydrolyzable or condensed tannin. Some methods for quantification of total polyphenol content in vitro are based on colorimetric measurements. Some tests are relatively specific to polyphenols (for instance the Porter's assay). Total phenols (or antioxidant effect) can be measured using the Folin–Ciocalteu reaction. Results are typically expressed as gallic acid equivalents. Polyphenols are seldom evaluated by antibody technologies. Other tests measure the antioxidant capacity of a fraction. Some make use of the ABTS radical cation which is reactive towards most antioxidants including phenolics, thiols and vitamin C. During this reaction, the blue ABTS radical cation is converted back to its colorless neutral form. The reaction may be monitored spectrophotometrically. This assay is often referred to as the Trolox equivalent antioxidant capacity (TEAC) assay. The reactivity of the various antioxidants tested are compared to that of Trolox, which is a vitamin E analog. Other antioxidant capacity assays which use Trolox as a standard include the diphenylpicrylhydrazyl (DPPH), oxygen radical absorbance capacity (ORAC), ferric reducing ability of plasma (FRAP) assays or inhibition of copper-catalyzed in vitro human low-density lipoprotein oxidation.
Russia attacked Kyiv with missiles and drones. Later in the day, at least nine people were killed and 29 others injured in a missile strike in Kryvyi Rih. Explosions were reported in Crimea and Krasnodar Krai according to local media. A Russian S-300 near Belbek airfield and two S-400s near Belbek and Sevastopol were destroyed according to Ukrainian officials. The US pledged another Patriot battery to Ukraine. Russia deployed S-500 batteries to Crimea, according to the HUR. A Ukrainian soldier claimed to have shot down a cruise missile using a machine gun, during a Russian air attack on Kyiv.
Sources: en.wikipedia.org
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.
Reversed-phase liquid chromatography estimates purity, and mass spectrometry confirms molecular mass. Together they distinguish the intended peptide from truncated or modified forms. Sequence-level confirmation may use tandem mass spectrometry or amino acid analysis.
Because it is not made under pharmaceutical standards, purity and content can vary between vendors and batches. Independent testing has documented labeling discrepancies. A certificate of analysis from an accredited laboratory offers more assurance than a vendor's own claim.
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.